Six Phase 3 / Pivotal Trials with Array's MEK Inhibitors Advancing BOULDER, Colo., June 2, 2014 /PRNewswire/ -- Two Array BioPharma-invented MEK inhibitors, binimetinib (MEK162) and selumetinib, were showcased at the 50th annual meeting of the American Society of Clinical Oncology (ASCO).  At the meeting, preliminary data for the combination of binimetinib and CDK4/6 inhibitor LEE011 (discovered by Novartis Institutes for BioMedical Research in collaboration with Astex Pharmaceuticals) from a Phase 1b/2 dose-escalation study conducted by Novartis in NRAS-mutant melanoma indicates the combination demonstrated an acceptable safety profile for most patients with promising preliminary...

Array to advance kinase inhibitors for inflammatory disease Biogen responsible for clinical development and worldwide commercialization BOULDER, Colo., May 28, 2014 /PRNewswire/ -- Array BioPharma (Nasdaq: ARRY) announced today a collaboration agreement with Biogen Idec (NASDAQ: BIIB) for the discovery and development of inhibitors targeting a novel kinase for the treatment of autoimmune disorders.  The collaboration target and lead inhibitors were discovered through Array's proprietary Kinase-Directed Phenotypic Screening Platform.   This technology relies on Array's deep experience in kinase inhibitor chemistry and phenotypic screening which can be applied to any therapeutic ...

BOULDER, Colo., May 27, 2014 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will present at the Jefferies 2014 Global Healthcare Conference in New York City.  The public is welcome to participate in the conference through a webcast on the Array BioPharma website.    Event: Jefferies 2014 Global Healthcare Conference Presenter: Ron Squarer, Chief Executive Officer Date: Wednesday, June 4, 2014 Time: 3:00 p.m. Eastern Time Webcast: www.arraybiopharma.com About Array BioPharma Array BioPharma Inc. is a ...

Appoints Nicholas A. Saccomano, Ph.D. as Chief Scientific Officer and Robert E. Winkler, M.D. as Vice President of Clinical Development BOULDER, Colo., May 19, 2014 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY), a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, today announced the appointments of Nicholas A. Saccomano, Ph.D., as Chief Scientific Officer and Robert E. Winkler, M.D., as Vice President of Clinical Research and Development.  Dr. Saccomano will oversee Array's discovery efforts and chemistry, manufacturing and controls (CMC) activities as a member of the exec...

BOULDER, Colo., May 14, 2014 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced presentations on its MEK inhibitors, binimetinib (MEK162) (co-developing with Novartis) and selumetinib (licensed to AstraZeneca) at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 30 – June 3, 2014 in Chicago, Illinois.  Both MEK inhibitors are advancing in Phase 3 or pivotal trials:  binimetinib is being evaluated in NRAS- and BRAF-mutant melanoma and low-grade serous ovarian cancer.  In addition, selumetinib is being evaluated in non-small cell lung cancer, uveal melanoma and thyroid cancer.  Ron Squarer, Chief Executive Offic...

BOULDER, Colo., May 12, 2014 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will present at the Bank of America Merrill Lynch Healthcare Conference in Las Vegas and the UBS Global Healthcare Conference in New York City.  The public is welcome to participate in the conferences through webcasts on the Array BioPharma website:  www.arraybiopharma.com.    Event: Bank of America Merrill Lynch Healthcare Conference Date: Tuesday, May 13, 2014 Time: 12:00 p.m. PDT Location: Encore at the Wynn, Las Vegas, NV Event...

Binimetinib Continues to Advance in Clinical Development ASCO Accepts 16 Abstracts for Array-Invented Drugs Phase 2 Single Agent Trial (AfFIRM) of Filanesib Initiated Phase 2 Trial of ARRY-797 in Rare Cardiovascular Disease Enrolling BOULDER, Colo., April 29, 2014 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today reported results for the third quarter of its fiscal year ending June 30, 2014. Revenue for the third quarter of fiscal 2014 was $7.8 million, compared to $10.0 million for the same period last year.  Revenue decreased due to reduction in recognition of license and milestone payments from our original Celgene Collaboration which ended in 2013....

Industry veteran brings additional oncology drug development experience BOULDER, Colo., April 28, 2014 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced that as part of its continued evolution toward late-stage development and commercialization, Charles M. Baum, M.D., Ph.D., President and Chief Executive Officer of Mirati Therapeutics, joined the company's board of directors, effective April 25, 2014. Dr. Baum has served as the President and Chief Executive Officer of Mirati since 2012.  Previously, he was the Senior Vice President for Clinical Research within Pfizer's Worldwide Research & Development division. Dr. Baum had worked at Pfizer from 2003 until ...

BOULDER, Colo., April 23, 2014 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the third quarter of fiscal 2014 and hold a conference call to discuss those results on Tuesday, April 29, 2014. Ron Squarer, Chief Executive Officer and Michael Carruthers, Chief Financial Officer will lead the call.   Conference Call Information Date: Tuesday, April 29, 2014 Time: 9:00 a.m. eastern time Toll-Free: (800) 708-4540 Toll: (847) 619-6397 Pass Code: 36946658 Webcast, including Replay and Conference Call Slides: htt...

Three Phase 3 Trials Advancing in Patients with BRAF Melanoma, NRAS Melanoma and Low-Grade Serous Ovarian Cancer BOULDER, Colo., April 23, 2014 /PRNewswire/ -- Following the recent announcement by Novartis and GlaxoSmithKline that they have entered into a definitive agreement to exchange certain assets, Array BioPharma Inc. (NASDAQ: ARRY) reports that Novartis has indicated that it will continue to honor its obligations under the Array-Novartis agreement relating to binimetinib (MEK162), including obligations relating to support for ongoing clinical trials as specified in the agreement. In April 2010, Array entered into an agreement under which Novartis received exclusive world...